Actionable mutations are now regularly identified in multiple myeloma, with such abnormalities as KRAS mutations, t(11;14), t(4;14), and CDKN2C loss being found in approximately 29%, 20%, 20%, and 15% of cases, respectively (6–9). Here, KRAS is linked to plasma cell myeloma.